← Leaderboards
Michele M Maxwell
Massachusetts General Hospital
$569,842
Attributed
$569,842
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $220.9K · FY2005–09$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$569,842 · 2
By mechanism
R21$420,570 · 1
F32$149,272 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jeffrey D Rothstein$32,739,978
- Davide Trotti$10,648,257
- Ru-Rong Ji$16,905,704
- Xandra Owens Breakefield$30,735,276
- Schahram Akbarian$48,610,378
Others in their field
Top investigators on “Amyotrophic Lateral Sclerosis”
- Merit E Cudkowicz · Massachusetts General Hospital$54,029,758
- James Dale Berry · Brigham And Women'S Hospital$37,291,450
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
- Suma Babu · Massachusetts General Hospital$36,168,406
- Jeffrey D Rothstein · Massachusetts General Hospital$22,909,620
- Teepu Siddique · University Of Chicago$22,641,778
Research focus
Amyotrophic Lateral SclerosisRna InterferenceAffectGene Induction /RepressionDesignBaseBrainEnzyme Induction /RepressionAnimalsAllelesGene ExpressionDisease ProgressionDoxycyclineBiological ModelsEngineeringBirthEvaluationExhibitsFamilial Amyotrophic Lateral SclerosisCritiquesFutureCuprozinc Superoxide DismutaseAnimal ModelGenes
Grant awards (5)
Target Validation for Neurogenerative Disease Using Conditional RNAi in vivo$199,643
R21 · FY2009 · NS · contact PI
Target Validation for Neurogenerative Disease Using Conditional RNAi in vivo$220,927
R21 · FY2008 · NS · contact PI
RNAi-mediated Silencing of Mutant Superoxide Dismutase$52,048
F32 · FY2006 · NS · contact PI
RNAi-mediated Silencing of Mutant Superoxide Dismutase$49,928
F32 · FY2005 · NS
RNAi-mediated Silencing of Mutant Superoxide Dismutase$47,296
F32 · FY2004 · NS